Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
The cases of 2 patients with nevirapine-associated hepatotoxicity in conjunction with rash and eosinophilia are reported here. Both patients' conditions improved following withdrawal of nevirapine. Previous case reports have described a variety of interventions other than drug withdrawal that might have contributed to resolution of drug-induced hepatitis. Until a better understanding of the clinical spectrum and pathophysiology of nevirapine-associated hepatotoxicity is realized, treatment will remain largely empiric.
Bundow
D
D
Division of Gastroenterology, Virginia Mason Medical Center, Seattle, USA.
Rosoff
L
L
Aboulafia
D M
DM
D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004342:Drug Hypersensitivity / Q000209:etiology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007565:Jaundice / Q000139:chemically induced*; D008297:Male; D019829:Nevirapine / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine